MeiraGTx Holdings plc 8-K

What Happened MeiraGTx Holdings plc filed a Form 8‑K on April 16, 2026 to announce positive three‑year results from its Phase 1 AQUAx study of AAV‑hAQP1 for grade 2/3 radiation‑induced xerostomia (RIX). Treatment was reported to be safe and well tolerated at all doses tested with no dose‑limiting toxicity or treatment‑related serious adverse events. Patient‑reported xerostomia scores (XQ) and unstimulated whole saliva flow rate (UWSFR) improvements observed at 12 months were maintained through 36 months.

Key Details

• Filing date: April 16, 2026 (Form 8‑K; press release filed as Exhibit 99.1).
• Safety: No dose‑limiting toxicity and no treatment‑related serious adverse events reported in the Phase 1 cohort.
• Patient outcomes: At 12 months, 63% of participants had ≥10‑point improvement in Xerostomia Questionnaire (XQ); 62% maintained ≥10‑point improvement at 36 months. Average XQ improvements at 12 months: unilateral +13 points, bilateral +21 points, overall +17 points (maintained to 36 months).
• Saliva flow: Overall UWSFR rose to 0.36 mL/min at 12 months (normal range 0.3–0.4 mL/min) and averaged 0.34 mL/min at 36 months.
• Commercial outlook: Company estimates ~165,000 U.S. patients and ~435,000 globally with persistent RIX; projects ~78% clinician preference (adjusted to ~52% projected usage), ~90% U.S. market access coverage, and peak global annual revenue potential of ~$3.7 billion (steady‑state ~$3.2B in late 2030s; U.S. peak ~$2.0B, steady ~$1.8B).

Why It Matters These data show durable clinical benefit and an acceptable safety profile in a condition with no effective disease‑modifying therapies, supporting AAV‑hAQP1’s continued clinical development and its potential commercial opportunity. For investors, the durability (36‑month maintenance of symptom and saliva‑flow improvements) and the company’s market estimates are the most material takeaways, but note the filing also contains forward‑looking statements and risks—revenue and adoption projections are management estimates and not guaranteed.